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Abstract 
At least 70 human RNA-binding proteins contain a prion-like domain (PrLD). 
PrLDs are low complexity domains which resemble in composition the 
infectious yeast prions. Mutations in PrLDs are associated to the onset of 
many neurodegenerative conditions, such as Amyotrophic Lateral Sclerosis 
(ALS). PrLDs are able to populate multiple physical states:  diffuse,  liquid  de-
mixed,  insoluble amyloid. Pathological mutations affect these equilibria in 
ways we cannot yet fully understand, or predict. The TAR DNA binding protein 
TDP-43 contains a 140 aa long PrLD and forms cytoplasmic aggregates in 
most cases of ALS. We use Deep Mutational Scanning to understand how 
sequence determines the toxicity of TDP-43 in a yeast model. I will present 









we quantify the effect of all possible amino acid substitutions in the PrLD on 
cellular fitness. While allowing us to understand the impact of mutations within 
low-complexity regions, these data provide the basis to understand by which 
mechanism protein inclusions drive pathogenesis. 
Short bio 
Benedetta Bolognesi graduated in 
Biotechnology from the University of Pavia, 
Italy, and carried out her PhD studies with Prof. 
Chris Dobson, at the department of Chemistry 
in Cambridge, UK. Here, she focussed on 
characterizing the biophysical properties of the 
Amyloid-Beta peptide. For her Post-Doc, 
Benedetta moved to the CRG, Barcelona, 
where she studied the ability of proteins to 
liquid de-mix in response to altered 
expression levels. She Joined IBEC with a junior group leader position in 
September 2018. Her lab builds mutational landscapes of intrinsically 
disordered proteins involved in neurodegeneration. 
 
